Corel Medical Series: Cancer/Corel Medical Series: Cancer.iso/mac/Program/Indexdat/indexa.T

Text File | 1997-01-27 | 4KB | 2 lines

T cells,7,Tamoxifen,5,Tanning booths,c37.8,Taste changes,p06.17;p17.22;p18.3;p18.16,Taxol,5,Taxotere,p35.14;c06.48,Technologist,p03.4,Tegretol,c05.26,Teratocarcinoma,c40.3,Teratoma,4,Testis diagram,c40.5,Testis cancer,12,Testis self-examination,p34.15;c40.7,delta-9-Tetrahydrocannabinol,p17.14,THC,chr.p17.14,Therapeutic radiologist,p06.3,Therapenbc ratio,p06.5,Thiethylperazine,chr.p17.14,Thioguanine,c18.13,6-Thioguanine,c18.13,Thiosulfate for ovarian cancer,c29.20,Thiotepa,p11.5;c04.18;c06.47;c25.15;c29.21,Thomsonianism,p13.5,Thoracoscow,p05.5,Thrush,p17.16;p17.18,Thymoma,c41.1,Thymus,c41.1,Thymus cancer,12,Thyroid cancer,14,Thyroid gland diagram,c42.6,Thyroidectomy,c42.14,Thyroiditis,c42.3,Tigan,p17.14;chr.p17.14,Tissue expansion breast reconstruction,rec.6;c06.21,TNM system of staging,p01.17,Tobacco,2,Topoisomerase I inhibitors,p35.8,Topotecan,p35.14;c06.48,Torecan,chr.p17.14,Toremifene,p35.15,Toxic shock syndrome,p11.5,Toxicity bone marrow,p12.10,Tracheal obstruction,p09.6,Traditional Indemnity Insurance,p32a.4,Tranquilizers,p17.23,Trans retinoic acid,p35.15,Transitional cell carcinoma,c02.1;c04.1;c35.32,Transplant center,p12.14,Transverse rectus abdominus myocutaneous flap technique,rec.1,Tranylcypromine sulfate,c08.13,Treatment,6,Treatment options,9,Tretinoin,p35.15,Trichomonas,c02.3,Trimethobenzamide,chr.p17.14,Trophoblastic disease,12,Tuberculosis,c05.20,Tuberous sclerosis,c05.2;c36.4,Tubular carcinoma,c06.4,Tumor,27,Tumor Board,p04.11,Tumor cell modulation immunotherapy,p08.6,Tumor infiltrating lymphocytes (TIL cells),p08.8,Tumor markers,2,Tumor names understanding,p01.13,Tumor necrosis factor (TNF),6,Tumor vaccines,p08.10;p08.17,Tumor-infiltrating lymphocytes,c25.18,Turner's syndrome,c40.4,Tylenol,p19.8,Tylox,p19.13,
defined,p04.5,gene therapy,p08.12,immune response,p08.3;p20.1,immunotherapy,p08.9,killer,p08.5,lymphomas,c24.1,suppressor,p08.4,for breast cancer,c06.24;c06.33;c06.47,for ovarian cancer,c29.21,for uterine cancer,c44.20,for vaginal cancer,c46.13,related drug,p35.15,for ovarian cancer,c29.13,for uterine cancer,c44.20,investigated,p35.6,related drug,p35.14,side effects,chr.p17.13,child,c10a.3,immature,c30.1,testis,c40.2,thyroid,c42.2,causes,c40.4,diagnosis,p34.15;c40.12,risk factors,c40.6,screening,c40.7,and sexuality,p23.7,spread,c40.3,staging,c40.15,symptoms,c40.8,treatment,c40.16,tumor markers,c40.9,types,c40.1,unknown primary site,c07.1,causes,c41.1,diagnosis,c41.6,follow-up,c41.11,questions to ask,c41.13,recurrence,c41.12,risk factors,c41.3,screening,c41.4,spread,c41.2,staging,c41.7,symptoms,c41.5,treatment,c41.8,types,c41.1,causes,c42.3,child,c10a.2,diagnosis,c42.9,follow-up,c42.25,questions to ask,c42.27,recurrence,c42.26,risk factors,c42.4,screening,c42.6,spread,c42.3,staging ,c42.13,symptoms,c42.8,treatment,c42.14,types,c42.1,unknown primary site,c07.3;c07.6;c07.1,irritates mouth,p17.19,risk factor,p01.7;p34.9;p34.15;c04.4;c14b.20;c17.3;c20.2,advances in,p33.7,future options,p33.10,genetic,p36.9,health care team,p03.4,PDQ guidelines,p37.3,and staging,p01.19,adjuvant therapy,p04.6,biological therapy,p04.5,chemotherapy,p04.4,choosing,p04.9,clinical trials,p04.16,combination therapies,p04.6,radiation therapy,p04.3,second opinions,p04.14,surgery,p04.3,causes,c43.3,diagnosis,c43.8,follow-up,c43.16,questions to ask,c43.18,recurrence,c43.17,risk factors,c43.4,screening,c43.6,spread,c43.3,staging,c43.10,symptoms,c43.7,treatment,c43.11,types,c43.1,ACTH-producing,c34.1,APUD,c08.1;c21.2,basaloid,c02.1,benign,p01.4,clear cell,c25.5;c29.1;c32.2;c44.2,cytological tests,p02.23,endodermal,c30.1;c46.1;c46.13,growth hormone-producing,c34.7,growth rate,p01.3;p01.15,high-grade,p01.16,low-grade,p01.16,malignant,p01.4;p01.12,midline,c07.13,mixed,c45.1,neuroendocrine,c08.1,non-functioning,c34.7,prolactin-producing,c34.1,pure,c45.1,recurrent,p05.6,residual,p05.6,solid,p35.14,spreading,p01.10,superficial,c04.2,types,p01.12,undifferentiated,p01.15,urachal,c04.3,well-differentiated,p01.15,testis,c40.9,tests for,p02.7,for bladder cancer,c04.18,for kidney cancer,c17.11,in biological therapy,p08.11,in hyperthermic perfusion,p11.5,investigational,p35.11,side effects,p08.17,